Novartis and Pfizer are among the companies best positioned to take advantage of future precision and personalised medicine disruption in the pharmaceuticals industry, our analysis shows.

The assessment comes from GlobalData’s Thematic Research ecosystem, which ranks companies on a scale of 1 to 5 based on their likelihood to tackle challenges like precision and personalised medicine and emerge as long-term winners of the pharmaceuticals sector.

According to our analysis, Novartis, Pfizer, Catalent, Johnson & Johnson, Roche, AstraZeneca, Sanofi, Bristol Myers Squibb, Amgen, Gilead Sciences, Patheon, Lonza, Takeda Pharmaceutical, Merck, Eli Lilly, IQVIA, AbbVie and Parexel are the companies best positioned to benefit from investments in precision and personalised medicine, all of them recording scores of 5 out of 5 in GlobalData’s Drug Development Thematic Scorecard.

The final column in the table represents the overall score given to that company when it comes to their current precision and personalised medicine position relative to their peers. A score of five indicates that a company is a dominant player in this space, while companies that score less than three are vulnerable to being left behind.

This article is based on GlobalData research figures as of 21 January 2022. For more up-to-date figures, check the GlobalData website.